The platform offers equipment and expertise in central nervous system imaging by Positron Emission Tomography (PET), Nuclear Magnetic Resonance (NMR), and Optical Imaging (OI).
PET: The platform's expertise is divided into three strategic areas: i) validation of radiotracers in animal models of human diseases, ii) validation of animal models using PET imaging and radiotracers, iii) evaluation of new therapies with a view to transferring them to clinical research. The PET platform interacts closely with the NMR and Histology platforms for the 3D reconstruction of multimodal images (MIRCEN / Image Processing).
NMR: High resolution imaging and multinuclear spectroscopy techniques (13C and 31P) are developed and validated: (i) optimised high-resolution NMR sequences of rodent and primate (T1, T2 and T2* weightings), (ii) optimised NMR sequences for rodent and primate 1H, 13C and 31P brain spectroscopy, automated quantification of short echo time spectra and (iii) CEST (chemical exchange saturation transfer) imaging of glutamate in rodent. Optimisation of complementary sequences can be carried out in the framework of collaborative projects.
IO: The activities usually supported are: i) in vivo biodistribution of macromolecules (aptamers, antibodies, peptides, nanoparticles, etc.), ii) in vivo monitoring of cell migration, differentiation and amplification, iii) in vivo imaging of gene expression.
18, route du Panorama
CEA Paris-Saclay, site de Fontenay-aux-Roses, MIRCen